Homestead Advisers Corp Has $4.80 Million Stake in Integer Holdings Corporation (NYSE:ITGR)

Homestead Advisers Corp decreased its holdings in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 32.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,670 shares of the medical equipment provider's stock after selling 19,600 shares during the period. Homestead Advisers Corp owned about 0.12% of Integer worth $4,799,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in ITGR. TD Private Client Wealth LLC grew its stake in shares of Integer by 5.8% in the 1st quarter. TD Private Client Wealth LLC now owns 1,524 shares of the medical equipment provider's stock valued at $180,000 after buying an additional 83 shares in the last quarter. HighPoint Advisor Group LLC boosted its position in Integer by 6.4% during the fourth quarter. HighPoint Advisor Group LLC now owns 1,684 shares of the medical equipment provider's stock worth $234,000 after purchasing an additional 101 shares during the period. Corient Private Wealth LLC boosted its position in Integer by 6.4% during the fourth quarter. Corient Private Wealth LLC now owns 1,969 shares of the medical equipment provider's stock worth $261,000 after purchasing an additional 118 shares during the period. Xponance Inc. boosted its position in Integer by 5.1% during the first quarter. Xponance Inc. now owns 2,518 shares of the medical equipment provider's stock worth $297,000 after purchasing an additional 122 shares during the period. Finally, Bessemer Group Inc. boosted its position in Integer by 73.1% during the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 125 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ITGR. Raymond James Financial upped their price target on Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a report on Friday, April 25th. KeyCorp cut their price target on Integer from $154.00 to $145.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Citigroup upgraded Integer from a "hold" rating to a "strong-buy" rating and upped their price target for the stock from $133.00 to $140.00 in a report on Thursday, May 22nd. Truist Financial set a $150.00 price target on Integer and gave the stock a "buy" rating in a report on Friday, April 25th. Finally, Wall Street Zen upgraded Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Integer presently has an average rating of "Moderate Buy" and a consensus target price of $146.25.

Integer Stock Up 2.2%

Shares of NYSE:ITGR traded up $2.50 during midday trading on Tuesday, hitting $114.05. The stock had a trading volume of 137,369 shares, compared to its average volume of 485,985. Integer Holdings Corporation has a 12 month low of $104.93 and a 12 month high of $146.36. The company has a quick ratio of 2.14, a current ratio of 3.40 and a debt-to-equity ratio of 0.78. The business's 50-day simple moving average is $119.65 and its 200-day simple moving average is $124.34. The company has a market cap of $3.98 billion, a P/E ratio of 54.05, a PEG ratio of 0.97 and a beta of 0.98.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. Integer had a return on equity of 11.95% and a net margin of 4.38%. The firm had revenue of $437.39 million for the quarter, compared to analyst estimates of $428.51 million. During the same period in the prior year, the firm posted $1.14 EPS. The company's revenue for the quarter was up 7.3% on a year-over-year basis. On average, sell-side analysts forecast that Integer Holdings Corporation will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Donald J. Spence sold 14,739 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the completion of the sale, the director directly owned 18,781 shares in the company, valued at $2,260,856.78. This represents a 43.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Martin C. Maxwell sold 8,720 shares of the stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the sale, the director directly owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. The trade was a 28.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 362,434 shares of company stock worth $44,577,115 in the last ninety days. 2.16% of the stock is owned by insiders.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.